Q1 Earnings Forecast for SINT Issued By HC Wainwright

Sintx Technologies, Inc. (NASDAQ:SINT) – Analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Sintx Technologies in a research note issued to investors on Monday, April 13th. HC Wainwright analyst B. Folkes anticipates that the company will earn ($0.77) per share for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. HC Wainwright also issued estimates for Sintx Technologies’ Q2 2026 earnings at ($0.78) EPS, Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.42) EPS, FY2026 earnings at ($2.15) EPS, FY2027 earnings at ($1.61) EPS, FY2028 earnings at ($0.89) EPS, FY2029 earnings at $0.89 EPS and FY2030 earnings at $1.54 EPS.

SINT has been the topic of a number of other reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sintx Technologies in a research report on Thursday, January 22nd. Ascendiant Capital Markets decreased their price target on shares of Sintx Technologies from $16.00 to $12.00 and set a “buy” rating for the company in a research report on Wednesday, April 8th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $11.00.

Sintx Technologies Stock Down 2.1%

Shares of NASDAQ SINT opened at $2.74 on Wednesday. Sintx Technologies has a fifty-two week low of $1.71 and a fifty-two week high of $6.78. The business has a 50 day moving average price of $2.76 and a two-hundred day moving average price of $3.35. The firm has a market cap of $11.29 million, a PE ratio of -0.48 and a beta of 0.66.

Hedge Funds Weigh In On Sintx Technologies

A number of hedge funds have recently bought and sold shares of SINT. Virtus Wealth Solutions LLC bought a new stake in shares of Sintx Technologies in the 3rd quarter valued at approximately $388,000. Geode Capital Management LLC lifted its stake in Sintx Technologies by 53.4% during the fourth quarter. Geode Capital Management LLC now owns 26,624 shares of the company’s stock worth $103,000 after purchasing an additional 9,265 shares during the last quarter. Finally, Veracity Capital LLC boosted its holdings in Sintx Technologies by 10.3% in the third quarter. Veracity Capital LLC now owns 79,928 shares of the company’s stock worth $327,000 after purchasing an additional 7,464 shares during the period. 18.38% of the stock is currently owned by institutional investors and hedge funds.

Key Sintx Technologies News

Here are the key news stories impacting Sintx Technologies this week:

• Positive Sentiment: HC Wainwright initiated coverage with a “Buy” and a $10 price target, publishing multi‑year estimates that project profitability by FY2029–FY2030 — a positive catalyst that can attract growth‑oriented investors. HC Wainwright Initiates Coverage on Sintx Technologies
• Positive Sentiment: Ascendiant Capital Markets maintains a “Buy” rating with a $12 target, supporting follow‑through demand from investors who track sell‑side coverage.
• Neutral Sentiment: Analysts’ models show a long runway: HC Wainwright forecasts meaningful losses through FY2026–FY2028 before EPS turns positive in FY2029–FY2030 — this signals high upside if commercial/clinical execution meets milestones but also longer timing risk.
• Negative Sentiment: Ascendiant trimmed near‑term EPS estimates slightly (Q1/Q2 2026 and FY2026 cuts), and both firms expect sizable losses in FY2026–FY2027 — near‑term earnings weakness increases downside risk and keeps the stock speculative.
• Negative Sentiment: Small market cap, negative trailing P/E, and the stock trading below its 200‑day moving average elevate volatility and downside risk for investors who prioritize liquidity and technical support.

About Sintx Technologies

Sintx Technologies, Inc (NASDAQ: SINT) is a medical materials company specializing in the development and manufacture of silicon nitride-based biomaterials for surgical and implantable medical devices. Its proprietary silicon nitride ceramic combines mechanical strength, biocompatibility and intrinsic antimicrobial properties, positioning it as an alternative to traditional metal and polymer implant materials. Sintx’s primary focus is on applications in spinal fusion, trauma fixation and dental implantology, where device performance and long-term biological response are critical.

The company’s core product offerings include silicon nitride powders for advanced implant fabrication and finished implantable components designed for interbody spinal fusion cages, spinal fixation hardware and trauma plates and screws.